Volume Alert - AGN 197.92 Allergan Inc $AGN Hit a
Post# of 58
Posted On: 11/12/2014 12:23:49 PM
Volume Alert - AGN 197.92 Allergan Inc $AGN Hit a high today of 199.98 Closing the day 10:30 at 197.92 +2.58 +1.32% With a day low of 192.12 and a total volume of 2,052,704.
AGN Recent Posts: http://investorshangout.com/Allergan-AGN-50031/
AGN Allergan Inc Recent Headline News
Regeneron/Sanofi Announce Positive Dupilumab Study Data - Analyst Blog
Zacks Equity Research - Zacks Investment Research - 1 hr 23 mins ago
Regeneron Pharmaceuticals, Inc. (REGN) and partner Sanofi (SNY) announced encouraging data from the interim analysis of a dose-ranging phase IIb study on dupilumab.
AGN: 196.52 (+1.18), ABBV: 63.91 (+0.06), SNY: 46.32 (-0.82), REGN: 400.23 (+1.87)
Bill Ackman's Latest Target: Zoetis Inc.
Todd Campbell, The Motley Fool - Motley Fool - 1 hr 42 mins ago
Source: Zoetis. Pershing Square's Bill Ackman is probably best known for his relentless advocacy regarding his short position in Herbalife , but he's also captured a lot of attention this year as being a key voice of support for the sale of ...
ZTS: 43.14 (-0.58), AGN: 196.52 (+1.18), HLF: 37.73 (+0.18), VRX: 130.55 (+0.52), PFE: 30.52 (+0.20), MRK: 59.31 (-0.06), LLY: 67.71 (-0.14)
5 Things Actavis plc's Management Wants You to Know
George Budwell, The Motley Fool - Motley Fool - Wed Nov 12, 8:21AM CST
The pharmaceutical industry has had a banner year in many ways, fueled by a slew of major drug approvals in recent years, numerous mergers and acquisitions, and significant corporate reorganizations that have helped to boost earnings. The specialty...
DRTX: 24.01 (+0.01), AGN: 196.52 (+1.18), ACT: 242.87 (-0.76), IRWD: 13.74 (-0.16), CBST: 71.58 (+0.16), PFE: 30.52 (+0.20)
Allergan tweaks bylaws pertaining to special meeting requests
Seeking Alpha - at Seeking Alpha - Wed Nov 12, 7:07AM CST
AGN: 196.52 (+1.18), VRX: 130.55 (+0.52)
Tracking The Parnassus Core Equity Fund
IVI Guy - at Seeking Alpha - Wed Nov 12, 6:45AM CST
WDFC: 77.24 (-0.42), SJR: 25.95 (-0.13), PRGO: 154.49 (-0.95), XYL: 37.48 (+0.13), CHRW: 72.60 (+0.85), MDLZ: 37.95 (+0.18), MKC: 73.18 (-0.04), MDU: 25.44 (-0.27), SYY: 38.90 (+0.38), PDCO: 44.73 (+0.46), PNR: 68.08 (-0.04), TRI: 38.05 (+0.13), UPS: 108.53 (-0.23), PEP: 97.37 (+0.67), AGN: 196.52 (+1.18), MSI: 63.65 (+0.10), NOV: 73.60 (+0.50), NWN: 47.01 (-0.48), EGN: 68.48 (-0.30), EBAY: 54.08 (-0.11), QCOM: 70.39 (+0.75), AMAT: 22.58 (+0.04), ACN: 84.14 (+0.20), AAPL: 111.01 (+1.31), MA: 84.67 (+0.08), SCHW: 28.87 (+0.02), STR: 23.85 (-0.44), SE: 39.05 (-0.28), GAS: 52.21 (-1.06), IRM: 38.10 (+0.27), WM: 49.49 (+0.13), CMP: 88.50 (+0.48), VRSK: 63.13 (+0.12), GILD: 106.81 (-1.20), EXPD: 44.31 (+0.05), TFX: 114.62 (+0.29), CVS: 89.59 (-0.17), PG: 89.76 (+0.09), PX: 126.34 (-0.36), NVS: 92.97 (+0.20)
Allergan Board of Directors Announces Approval of Amendments to Company's Bylaws
Business Wire - Wed Nov 12, 6:01AM CST
--Amendments Follow Meetings with Major Stockholders to Solicit Their Perspectives
AGN: 196.52 (+1.18)
Bristol-Myers Gives Updates on HCV Candidate Daclatasvir - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Nov 11, 5:41PM CST
Bristol-Myers Squibb Company (BMY) provided an update on its hepatitis C (HCV) candidate daclatasvir.
AGN: 196.52 (+1.18), GILD: 106.81 (-1.20), ABBV: 63.92 (+0.07), BMY: 58.79 (+0.07)
Bill Ackman vs. Allergan, Inc.: Who Will Win the War of Words?
George Budwell, The Motley Fool - Motley Fool - Tue Nov 11, 5:18PM CST
Irvine, Calif.-based Botox maker Allergan is desperately trying to fend off a takeover bid from Valeant Pharmaceuticals , a company with a history of buying rivals and slashing their work forces. In an interesting twist, this deal is being...
AGN: 196.52 (+1.18), VRX: 130.55 (+0.52), ACT: 242.87 (-0.76)
Dendreon Shares Plummet After It Files for Bankruptcy - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Nov 11, 3:45PM CST
Dendreon filed voluntary petitions under Chapter 11 of the Bankruptcy Code in the U.S. Bankruptcy Court for the District of Delaware.
MDVN: 107.26 (-0.03), AGN: 196.52 (+1.18), JNJ: 108.96 (+0.05), DNDN: 0.17 (+0.02)
Zoetis could be fallback option for Valeant
Seeking Alpha - at Seeking Alpha - Tue Nov 11, 3:16PM CST
AGN: 196.52 (+1.18), ZTS: 43.14 (-0.58), ACT: 242.87 (-0.76), VRX: 130.55 (+0.52)
Actavis Says 'Let's Make A Deal'
Bill Gunderson - Seeking Alpha - Tue Nov 11, 8:42AM CST
I wrote about generic and specialty drug company Actavis plc (NYSE: ACT ) a while back detailing the rumored love triangle between them, Allergan (NYSE: AGN ), Valeant Pharmaceuticals (NYSE: VRX ), and Salix Pharmaceuticals (NASDAQ: SLXP ). On...
DRTX: 24.01 (+0.01), AGN: 196.52 (+1.18), ACT: 242.87 (-0.76), VRX: 130.55 (+0.52), MDT: 68.75 (-0.24), SLXP: 96.74 (-2.27), SNY: 46.32 (-0.82)
New Survey Reveals What Women in the U.S. Really Want to Know About BOTOX® Cosmetic (onabotulinumtoxinA)
PR Newswire - Tue Nov 11, 7:47AM CST
Many women are familiar with the brand name BOTOX® Cosmetic (onabotulinumtoxinA), but a new study from SheSpeaks(TM), an online community of women, reveals what they really want to know about it.1 To address the most common questions women have - and there are nearly 10 million women who are considering treatment2 - Allergan, Inc., maker of BOTOX® Cosmetic, teamed up with SheSpeaks to identify these questions and provide answers.
AGN: 196.52 (+1.18)
Merck Reports Interim Data on Hepatitis C Virus Drug - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Nov 10, 3:45PM CST
Merck (MRK) presented interim data from a proof-of-concept study on its fixed-dose combination regimen - grazoprevir/elbasvir - in combination with Gilead's Sovaldi.
AGN: 196.52 (+1.18), GILD: 106.81 (-1.20), MRK: 59.32 (-0.05), ABBV: 63.92 (+0.07)
Salix Crashes on Inventory Issues, Lowered Outlook - Analyst Blog
Arpita Dutt - Zacks Investment Research - Mon Nov 10, 1:56PM CST
Salix's (SLXP) wholesale inventory levels for its products were much higher than previously announced.
AGN: 196.52 (+1.18), VRX: 130.55 (+0.52), AUXL: 32.61 (+0.01), SLXP: 96.74 (-2.27)
Emergent BioSolutions Beats on Q3 Earnings, Guidance Up - Analyst Blog
Lopamudra Bhattacharya - Zacks Investment Research - Mon Nov 10, 11:30AM CST
Emergent BioSolutions reported third quarter earnings of 67 cents per share.
AGN: 196.52 (+1.18), EBS: 24.75 (+0.34), ABAX: 53.42 (-0.08), ABBV: 63.92 (+0.07)
Gilead (GILD) Submits HIV Combination Drug for FDA Review - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Nov 07, 5:50PM CST
Gilead Sciences, Inc. announced that it has submitted a New Drug Application to the FDA for its tenofovir alafenamide-based single tablet regimen.
AGN: 196.52 (+1.18), JNJ: 108.96 (+0.05), GILD: 106.81 (-1.20), ABBV: 63.92 (+0.07)
Novartis' (NVS) LBH589 Gets Unfavorable FDA Panel Opinion - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Nov 07, 4:20PM CST
Novartis (NVS) received disappointing news when the FDA's Oncologic Drugs Advisory Committee (ODAC) did not recommend its pipeline candidate LBH589.
AGN: 196.52 (+1.18), ABBV: 63.92 (+0.07), BMY: 58.79 (+0.07), NVS: 92.97 (+0.20)
Stock Movers: Why These 4 Medical Stocks Dived Today
at Investor's Business Daily - Fri Nov 07, 3:36PM CST
Raised eyebrows can lead to declining stock prices. Stocks On The Move down today include Salix Pharmaceuticals (SLXP), embroiled in drama as questions of accuracy and honesty cloud the drugmaker's weak Q3 results. Are its inventories accurate, and...
AGN: 196.52 (+1.18), VRX: 130.55 (+0.52), DVA: 76.17 (+0.04), GILD: 106.81 (-1.20), SLXP: 96.74 (-2.27), ICPT: 161.96 (-11.17), HUM: 137.12 (+0.68)
Ride The Smart-Money Coattails: Use IBD's Funds Pages
at Investor's Business Daily - Fri Nov 07, 3:10PM CST
Selecting stocks that have superior profit and sales growth is not the sole key to success in the market. Neither is simply buying stocks with outstanding price strength. Before you invest in a stock, make sure that it also is a favorite among the...
AGN: 196.52 (+1.18), HCA: 65.13 (-0.88), BIDU: 248.57 (-1.77), ZBRA: 72.47 (+0.20), SWKS: 61.48 (+0.51), ALK: 55.70 (-0.44), CELG: 107.65 (-0.20)
AstraZeneca (AZN) Misses on Q3 Earnings, Raises Guidance - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Nov 07, 2:20PM CST
AstraZeneca (AZN) reported third-quarter 2014 core earnings of $1.05 per ADS that missed the Zacks Consensus Estimate by a penny.
AGN: 196.52 (+1.18), AZN: 74.35 (+0.15), ABBV: 63.92 (+0.07), AEGR: 21.20 (-0.36)
AGN Recent Posts: http://investorshangout.com/Allergan-AGN-50031/
AGN Allergan Inc Recent Headline News
Regeneron/Sanofi Announce Positive Dupilumab Study Data - Analyst Blog
Zacks Equity Research - Zacks Investment Research - 1 hr 23 mins ago
Regeneron Pharmaceuticals, Inc. (REGN) and partner Sanofi (SNY) announced encouraging data from the interim analysis of a dose-ranging phase IIb study on dupilumab.
AGN: 196.52 (+1.18), ABBV: 63.91 (+0.06), SNY: 46.32 (-0.82), REGN: 400.23 (+1.87)
Bill Ackman's Latest Target: Zoetis Inc.
Todd Campbell, The Motley Fool - Motley Fool - 1 hr 42 mins ago
Source: Zoetis. Pershing Square's Bill Ackman is probably best known for his relentless advocacy regarding his short position in Herbalife , but he's also captured a lot of attention this year as being a key voice of support for the sale of ...
ZTS: 43.14 (-0.58), AGN: 196.52 (+1.18), HLF: 37.73 (+0.18), VRX: 130.55 (+0.52), PFE: 30.52 (+0.20), MRK: 59.31 (-0.06), LLY: 67.71 (-0.14)
5 Things Actavis plc's Management Wants You to Know
George Budwell, The Motley Fool - Motley Fool - Wed Nov 12, 8:21AM CST
The pharmaceutical industry has had a banner year in many ways, fueled by a slew of major drug approvals in recent years, numerous mergers and acquisitions, and significant corporate reorganizations that have helped to boost earnings. The specialty...
DRTX: 24.01 (+0.01), AGN: 196.52 (+1.18), ACT: 242.87 (-0.76), IRWD: 13.74 (-0.16), CBST: 71.58 (+0.16), PFE: 30.52 (+0.20)
Allergan tweaks bylaws pertaining to special meeting requests
Seeking Alpha - at Seeking Alpha - Wed Nov 12, 7:07AM CST
AGN: 196.52 (+1.18), VRX: 130.55 (+0.52)
Tracking The Parnassus Core Equity Fund
IVI Guy - at Seeking Alpha - Wed Nov 12, 6:45AM CST
WDFC: 77.24 (-0.42), SJR: 25.95 (-0.13), PRGO: 154.49 (-0.95), XYL: 37.48 (+0.13), CHRW: 72.60 (+0.85), MDLZ: 37.95 (+0.18), MKC: 73.18 (-0.04), MDU: 25.44 (-0.27), SYY: 38.90 (+0.38), PDCO: 44.73 (+0.46), PNR: 68.08 (-0.04), TRI: 38.05 (+0.13), UPS: 108.53 (-0.23), PEP: 97.37 (+0.67), AGN: 196.52 (+1.18), MSI: 63.65 (+0.10), NOV: 73.60 (+0.50), NWN: 47.01 (-0.48), EGN: 68.48 (-0.30), EBAY: 54.08 (-0.11), QCOM: 70.39 (+0.75), AMAT: 22.58 (+0.04), ACN: 84.14 (+0.20), AAPL: 111.01 (+1.31), MA: 84.67 (+0.08), SCHW: 28.87 (+0.02), STR: 23.85 (-0.44), SE: 39.05 (-0.28), GAS: 52.21 (-1.06), IRM: 38.10 (+0.27), WM: 49.49 (+0.13), CMP: 88.50 (+0.48), VRSK: 63.13 (+0.12), GILD: 106.81 (-1.20), EXPD: 44.31 (+0.05), TFX: 114.62 (+0.29), CVS: 89.59 (-0.17), PG: 89.76 (+0.09), PX: 126.34 (-0.36), NVS: 92.97 (+0.20)
Allergan Board of Directors Announces Approval of Amendments to Company's Bylaws
Business Wire - Wed Nov 12, 6:01AM CST
--Amendments Follow Meetings with Major Stockholders to Solicit Their Perspectives
AGN: 196.52 (+1.18)
Bristol-Myers Gives Updates on HCV Candidate Daclatasvir - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Nov 11, 5:41PM CST
Bristol-Myers Squibb Company (BMY) provided an update on its hepatitis C (HCV) candidate daclatasvir.
AGN: 196.52 (+1.18), GILD: 106.81 (-1.20), ABBV: 63.92 (+0.07), BMY: 58.79 (+0.07)
Bill Ackman vs. Allergan, Inc.: Who Will Win the War of Words?
George Budwell, The Motley Fool - Motley Fool - Tue Nov 11, 5:18PM CST
Irvine, Calif.-based Botox maker Allergan is desperately trying to fend off a takeover bid from Valeant Pharmaceuticals , a company with a history of buying rivals and slashing their work forces. In an interesting twist, this deal is being...
AGN: 196.52 (+1.18), VRX: 130.55 (+0.52), ACT: 242.87 (-0.76)
Dendreon Shares Plummet After It Files for Bankruptcy - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Nov 11, 3:45PM CST
Dendreon filed voluntary petitions under Chapter 11 of the Bankruptcy Code in the U.S. Bankruptcy Court for the District of Delaware.
MDVN: 107.26 (-0.03), AGN: 196.52 (+1.18), JNJ: 108.96 (+0.05), DNDN: 0.17 (+0.02)
Zoetis could be fallback option for Valeant
Seeking Alpha - at Seeking Alpha - Tue Nov 11, 3:16PM CST
AGN: 196.52 (+1.18), ZTS: 43.14 (-0.58), ACT: 242.87 (-0.76), VRX: 130.55 (+0.52)
Actavis Says 'Let's Make A Deal'
Bill Gunderson - Seeking Alpha - Tue Nov 11, 8:42AM CST
I wrote about generic and specialty drug company Actavis plc (NYSE: ACT ) a while back detailing the rumored love triangle between them, Allergan (NYSE: AGN ), Valeant Pharmaceuticals (NYSE: VRX ), and Salix Pharmaceuticals (NASDAQ: SLXP ). On...
DRTX: 24.01 (+0.01), AGN: 196.52 (+1.18), ACT: 242.87 (-0.76), VRX: 130.55 (+0.52), MDT: 68.75 (-0.24), SLXP: 96.74 (-2.27), SNY: 46.32 (-0.82)
New Survey Reveals What Women in the U.S. Really Want to Know About BOTOX® Cosmetic (onabotulinumtoxinA)
PR Newswire - Tue Nov 11, 7:47AM CST
Many women are familiar with the brand name BOTOX® Cosmetic (onabotulinumtoxinA), but a new study from SheSpeaks(TM), an online community of women, reveals what they really want to know about it.1 To address the most common questions women have - and there are nearly 10 million women who are considering treatment2 - Allergan, Inc., maker of BOTOX® Cosmetic, teamed up with SheSpeaks to identify these questions and provide answers.
AGN: 196.52 (+1.18)
Merck Reports Interim Data on Hepatitis C Virus Drug - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Nov 10, 3:45PM CST
Merck (MRK) presented interim data from a proof-of-concept study on its fixed-dose combination regimen - grazoprevir/elbasvir - in combination with Gilead's Sovaldi.
AGN: 196.52 (+1.18), GILD: 106.81 (-1.20), MRK: 59.32 (-0.05), ABBV: 63.92 (+0.07)
Salix Crashes on Inventory Issues, Lowered Outlook - Analyst Blog
Arpita Dutt - Zacks Investment Research - Mon Nov 10, 1:56PM CST
Salix's (SLXP) wholesale inventory levels for its products were much higher than previously announced.
AGN: 196.52 (+1.18), VRX: 130.55 (+0.52), AUXL: 32.61 (+0.01), SLXP: 96.74 (-2.27)
Emergent BioSolutions Beats on Q3 Earnings, Guidance Up - Analyst Blog
Lopamudra Bhattacharya - Zacks Investment Research - Mon Nov 10, 11:30AM CST
Emergent BioSolutions reported third quarter earnings of 67 cents per share.
AGN: 196.52 (+1.18), EBS: 24.75 (+0.34), ABAX: 53.42 (-0.08), ABBV: 63.92 (+0.07)
Gilead (GILD) Submits HIV Combination Drug for FDA Review - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Nov 07, 5:50PM CST
Gilead Sciences, Inc. announced that it has submitted a New Drug Application to the FDA for its tenofovir alafenamide-based single tablet regimen.
AGN: 196.52 (+1.18), JNJ: 108.96 (+0.05), GILD: 106.81 (-1.20), ABBV: 63.92 (+0.07)
Novartis' (NVS) LBH589 Gets Unfavorable FDA Panel Opinion - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Nov 07, 4:20PM CST
Novartis (NVS) received disappointing news when the FDA's Oncologic Drugs Advisory Committee (ODAC) did not recommend its pipeline candidate LBH589.
AGN: 196.52 (+1.18), ABBV: 63.92 (+0.07), BMY: 58.79 (+0.07), NVS: 92.97 (+0.20)
Stock Movers: Why These 4 Medical Stocks Dived Today
at Investor's Business Daily - Fri Nov 07, 3:36PM CST
Raised eyebrows can lead to declining stock prices. Stocks On The Move down today include Salix Pharmaceuticals (SLXP), embroiled in drama as questions of accuracy and honesty cloud the drugmaker's weak Q3 results. Are its inventories accurate, and...
AGN: 196.52 (+1.18), VRX: 130.55 (+0.52), DVA: 76.17 (+0.04), GILD: 106.81 (-1.20), SLXP: 96.74 (-2.27), ICPT: 161.96 (-11.17), HUM: 137.12 (+0.68)
Ride The Smart-Money Coattails: Use IBD's Funds Pages
at Investor's Business Daily - Fri Nov 07, 3:10PM CST
Selecting stocks that have superior profit and sales growth is not the sole key to success in the market. Neither is simply buying stocks with outstanding price strength. Before you invest in a stock, make sure that it also is a favorite among the...
AGN: 196.52 (+1.18), HCA: 65.13 (-0.88), BIDU: 248.57 (-1.77), ZBRA: 72.47 (+0.20), SWKS: 61.48 (+0.51), ALK: 55.70 (-0.44), CELG: 107.65 (-0.20)
AstraZeneca (AZN) Misses on Q3 Earnings, Raises Guidance - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Nov 07, 2:20PM CST
AstraZeneca (AZN) reported third-quarter 2014 core earnings of $1.05 per ADS that missed the Zacks Consensus Estimate by a penny.
AGN: 196.52 (+1.18), AZN: 74.35 (+0.15), ABBV: 63.92 (+0.07), AEGR: 21.20 (-0.36)
(0)
(0)Allergan Inc. (AGN) Stock Research Links
Scroll down for more posts ▼